Welcome to our dedicated page for Immix Biopharma news (Ticker: IMMX), a resource for investors and traders seeking the latest updates and insights on Immix Biopharma stock.
Immix Biopharma, Inc. (Nasdaq: IMMX) generates a steady flow of news as a clinical-stage biopharmaceutical company advancing cell therapies for relapsed/refractory AL amyloidosis and other serious diseases. The company describes itself as a global leader in this rare blood disorder, and its news coverage reflects progress in clinical development, regulatory interactions, capital formation and corporate governance.
Many Immix Biopharma news items focus on its lead BCMA-targeted CAR-T cell therapy, NXC-201, and the ongoing NEXICART-2 clinical trial in relapsed/refractory AL amyloidosis. Press releases highlight interim and Phase 2 results, including complete response rates, organ responses and safety observations, as well as the selection of NXC-201 data for oral presentations at major conferences such as ASH and ASCO. The company also reports on regulatory designations for NXC-201, including RMAT and Orphan Drug Designation from U.S. and European authorities.
Investors following IMMX news will also see announcements about equity financings, including registered underwritten offerings and private placements of common stock and warrants, together with stated uses of proceeds for NXC-201 development and general corporate purposes. Additional coverage includes board and management changes, such as the appointment of experienced biotechnology leaders to the board of directors and the addition of a Chief Commercial Officer to prepare for potential commercialization of NXC-201.
This news page aggregates company press releases and related updates so readers can track Immix Biopharma’s clinical milestones, financing activities, conference presentations and strategic appointments over time.
Nexcella, a subsidiary of Immix Biopharma (NASDAQ: IMMX), reported promising clinical data from its Phase 1b/2 NEXICART-1 trial (NCT04720313) for NXC-201, a CAR-T therapy targeting relapsed/refractory multiple myeloma and AL amyloidosis. The data indicated a 92% overall response rate in multiple myeloma and a 100% response rate in AL amyloidosis patients, with median progression-free survival of 12.3 months. These results were presented at the EBMT 49th Annual Meeting in Paris. Nexcella aims to submit a BLA for FDA approval in both conditions after treating 100 patients for multiple myeloma and 30-40 for AL amyloidosis. The markets for multiple myeloma and AL amyloidosis are projected to expand significantly by 2027 and 2025, respectively, presenting substantial commercial opportunities for NXC-201.
Nexcella Inc., a subsidiary of Immix Biopharma (NASDAQ: IMMX), announced the presentation of updated clinical data for NXC-201, a CAR-T therapy for multiple myeloma and AL amyloidosis, at the 49th annual meeting of the European Society for Blood and Marrow Transplantation in Paris from April 23-26, 2023.
The updated data show a 90% overall response rate and a 59% complete response rate in relapsed/refractory multiple myeloma. Notably, NXC-201 achieved a 100% hematologic and organ response rate in AL amyloidosis patients. These results reflect the potential of NXC-201 as the first outpatient CAR-T therapy for these conditions.
FAQ
What is the current stock price of Immix Biopharma (IMMX)?
What is the market cap of Immix Biopharma (IMMX)?
